ESBATech AG (Zurich, Switzerland) has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops.
ESBATech AG (Zurich, Switzerland) has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops. These data were confirmed in several independent preclinical in vivo tests.
Anticipated therapeutic concentrations of ESBATech’s antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including the vitreous humor, retina, and choroid. ESBATech’s lead antibody fragment, ESBA105, is a TNF-alpha antagonist that is scheduled to enter clinical development later in 2008.
Antibody fragments are an emerging area of focus within the monoclonal antibody market and represent a new class of therapeutics. Because of their smaller molecular size, antibody fragments have a number of advantages over whole antibodies. Antibody fragments comprise only the naturally occurring antigen-binding pocket of the monoclonal antibody, and not the Fc part that is required to trigger an immune response. This new class of new products opens applications in indications where no such immune response is required. Thus, endogenous proteins are preferred targets for these new biologics.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.